Digital Therapeutics Market Global Report 2026

The digital therapeutics market size has grown exponentially in recent years. It will grow from $10.96 billion in 2025 to $14.11 billion in 2026 at a compound annual growth rate (CAGR) of 28.8%. The growth during the historic period can be attributed to increasing smartphone penetration in healthcare, growing acceptance of digital health solutions, expansion of telemedicine services, early regulatory approvals for digital therapeutics, and the rising burden of chronic diseases.

The digital therapeutics market size is expected to see exponential growth in the next few years. It will grow to $38.19 billion in 2030 at a compound annual growth rate (CAGR) of 28.3%. The growth during the forecast period can be attributed to increasing reimbursement support for digital therapeutics, rising demand for personalized digital care, expansion of AI-driven treatment platforms, growing partnerships between healthcare providers and technology firms, and increasing emphasis on preventive digital health. Major trends in the forecast period include increasing adoption of software-based therapeutic solutions, greater integration of wearable health devices, growing use of remote patient monitoring platforms, expansion of evidence-based digital care programs, and enhanced focus on personalized treatment pathways.

The growing prevalence of chronic diseases is expected to support the growth of the digital therapeutics market going forward. Chronic diseases are long-term conditions that generally persist for one year or longer and require continuous medical care or restrict daily activities, or both. Digital therapeutics are software-based interventions that provide evidence-based therapeutic treatments to patients, supporting chronic disease management and expanding available treatment options. For instance, in March 2025, according to the Office for Health Improvement & Disparities (OHID), a UK-based unit of the Department of Health and Social Care, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over in England was 7.0% in March 2024, up from 6.8% in March 2023. Therefore, the growing prevalence of chronic diseases is driving the growth of the digital therapeutics market.

Major companies operating in the digital therapeutics market are concentrating on technological advancements such as prescription-only digital behavioral therapy platforms to increase treatment accessibility, strengthen patient engagement, and deliver clinically validated outcomes. A prescription-only digital behavioral therapy platform uses software-based interventions delivered through smartphones or tablets, incorporating evidence-based modules such as cognitive behavioral therapy (CBT), remote monitoring, and interactive goal tracking. These platforms enable scalable, drug-free disease management while providing personalized patient support. For instance, in July 2023, Better Therapeutics, a US-based prescription digital therapeutics company, launched AspyreRx (formerly BT-001), a digital therapeutic designed for type 2 diabetes. The product provides a 90-day self-paced program through a smartphone application, incorporating weekly CBT lessons, personalized goal-setting, and tracking of blood glucose and lifestyle data; clinical trials showed sustained reductions in HbA1c, improvements in weight, and enhanced quality-of-life outcomes.

In July 2023, Big Health, a US-based provider of digital therapeutics, acquired Limbix for an undisclosed amount. The acquisition is expected to expand Big Health’s existing product portfolio, which includes Sleepio for insomnia and Daylight for anxiety, by adding Limbix’s SparkRx and another teenage medication in development for anxiety. Limbix is a US-based provider of digital therapeutics.

Major companies operating in the digital therapeutics market are Omada Health Inc., WellDoc Inc., 2Morrow Inc., Propeller Health, Pear Therapeutics, Canary Health Inc., Noom Health Inc., Akili Interactive Labs, Better Therapeutics, Happify Health, Kaia Health, Medtronic plc, Teladoc Health Inc., Fitbit Health Solutions, EMulate Therapeutics, BigHealth, DarioHealth, IQVIA, JOGO Health, SilverCloud Health, Biofourmis Inc., Prosoma, Virta Health Corp., One Drop Inc., Lark Health, Xealth, CogniFit Ltd.

North America was the largest region in the digital therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the digital therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.